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INTRODUCTION
Psoriasis is a chronic inflammatory systemic disease predominantly affecting the skin and joints. The prevalence ranges between 0.9% (United States) and 8.5% (Norway) [1] . Skin lesions are the major manifestation of the disease. They are described as scaling and erythematous plaques that may be pruritic or painful and cause significant quality of life issues [2] .
The new era of biologic therapies offers outstanding options for the treatment of chronic plaque psoriasis, and these agents have proved to be remarkable in improving patient quality of life compared with classical antipsoriatic treatments. However, despite the high efficacy, there have always been concerns regarding the safety of these agents as all antitumor necrosis factor alpha (anti-TNF-alpha) agents have been associated with activation of latent tuberculosis infection (LTBI) in a relatively short period of time [3] . According to World Health Organization (WHO), the global incidence of tuberculosis (TB) is estimated to 125 cases per 100,000 population [4] . The progression or reactivation of TB should be expected and such concerns have led to intensive screening and monitoring of patients receiving anti-TNF therapies [5] . Current screening includes medical history, chest X-ray, and tests for evaluating the immunologic response to the presence of Mycobacterium tuberculosis, such as the tuberculin skin test (TST) and interferon gamma release assays (IGRAs) [6] . Current guidelines recommend TST as the main screening tool for LTBI in patients with psoriasis before initiation of anti-TNF therapy, but there is a lack of consensus on the interpretation of TST in this group of patients [7] [8] [9] . The European S3 guidelines recommend the use of either TST or IGRAs or both for LTBI detection [10] . However, as TST may produce false-positive results, the newest recommendations suggest the use of IGRAs [11] .
Despite the screening programs for LTBI identification prior to anti-TNF therapy, the risk of developing active TB is still present. We report a patient with psoriasis who had a negative TST during screening and later developed active TB under adalimumab therapy. We also report two patients with challenging aspects regarding the diagnosis and management of LTBI in relation to anti-TNF therapy. Additional evidence from a review of the literature is also discussed.
CASE STUDIES
Patient characteristics, TB status, and treatment received for all three case studies are summarized in Table 1 .
Case 1
A 57-year-old man presented with a 18-year history of severe chronic plaque psoriasis. The patient was hypertensive. He was previously treated with systemic methotrexate and topical antipsoriatic therapies. He did not report any known contact with a case of active TB.
Due to the poor response to classical treatments for psoriasis, adalimumab was recommended according to current guidelines [2] . All screening tests were within normal ranges, including a negative TST (3 mm induration) and chest X-ray. Therefore, adalimumab therapy was initiated without antituberculous chemoprophylaxis. The patient showed a good and stable response; the Psoriasis Area and Severity Index (PASI)
decreased from 36 to 9 in 12 weeks, and all lesions were cleared after 6 months of treatment.
After 18 months of biologic therapy, the patient complained of a mild but persistent In contrast, TNF-blockade is associated with granuloma lysis [9, 15] .
Many randomized, controlled studies have evaluated the safety of etanercept, infliximab, and adalimumab [16, 17] , the majority of which have been conducted in patients with rheumatologic conditions or Crohn's disease.
However, according to the Food and Drug Administration (FDA) Adverse Event Reporting System (AERS), only a single case of TB occurred during initial clinical trials of infliximab [18] and none of the patients treated with etanercept and adalimumab developed TB during the initial studies [9] . Despite these results, TB has been continuously reported in association with biologic therapy [19] [20] [21] [22] .
Data from the British Society for [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] were identified that collectively included 3,657 adult patients with moderate-to-severe psoriasis who were treated with adalimumab, etanercept, or infliximab ( Table 2 ). The total number of patients receiving the placebo was 1,709. The treatment duration ranged from 12 to 52 weeks.
All trials compared anti-TNF agents with the placebo: three trials with adalimumab, six trials with etanercept, and four trials with infliximab. Three studies [29, 40, 41] reported active TB as an adverse event occurring during anti-TNF therapy: one patient was treated with adalimumab and five patients received infliximab. Active TB was not reported in the placebo group.
Although clinical trials have demonstrated significant efficacy and a low number of TB cases in patients with psoriasis, questions remain about the long-term use of these agents. There are several limitations that make it difficult to assess the potential for anti-TNF therapy to promote TB infection. For example, the median time to TB diagnosis has been reported to range from 5.5 to 18.5 months [20] , and these randomized, controlled studies extend to a limited period of time (3-13 months). From another point of view, the study of Yang et al. [41] highlights that TB is a major problem in endemic areas. Although current guidelines recommend screening prior to anti-TNF therapy, there are no standard indications and there is a lack of consensus on interpreting TST in patients with psoriasis. The consensus guidelines from the National Psoriasis Foundation, USA, state that an induration [5 mm is classified as positive in patients with immunosuppression, including patients who are receiving TNF antagonists [7] . The main disadvantage is that they do not provide specific guidelines on interpreting TST for patients about to start anti-TNF therapy [8] .
Some authors consider that skin indurations of 5 mm or greater should be interpreted as a positive result for LTBI in any patient considered for TNF blockade [65] . This cut-off value is accepted by most guidelines, including the national guidelines, but it may overestimate LTBI in psoriatic patients, leading to unnecessary treatments. The present authors previously reported that patients with moderate-to-severe psoriasis had positive TST reactions more frequently (70.5%) than nondermatologic subjects (51%) [66] . Although the TST still represents a useful method, it is difficult to perform and read in psoriatic patients with extensive lesions, because these patients rarely present clinically unaffected skin for testing. Moreover, important immunologic mechanisms take place in even apparently healthy skin of psoriatic patients; the proinflammatory state can lead to an overreaction to antigenic triggers [67] . Another factor that may lead to false-positive results is the Koebner phenomenon (development of psoriatic lesions at the site of trauma), reported after intradermal injection of purified protein derivative (PPD) in psoriatic patients [68] . In contrast, psoriatic patients with negative TST results and positive QFT-G results have been reported [69] [70] [71] . The reversion of a positive TST result to a negative result may also occur [72] .
Thus, to minimize the risk of false-negative results, some authors propose a booster dose 7-10 days after an initially negative TST [73] .
Tubach et al. [3] reported 69 cases of TB in patients treated with anti-TNF agents, two-thirds of which occurred in patients with negative TST results at screening. However, the authors [74] . Although QFT-G demonstrates high specificity for LTBI (96-99%), its sensitivity is still questionable (70-78%) [75] . In one study, LTBI treatment was avoided in 20% of patients with positive TST results but negative IGRA results [76] .
The use of both methods in parallel can enhance both sensitivity and specificity.
Furthermore, routine periodic retesting during therapy could allow for the detection of possible conversions. However, serial TST testing is not strictly recommended due to the boosting effect [60] . There is also evidence that the TST can boost subsequent IGRA results. The effect is evident after the first 3 days post-TST testing and potentially wanes after a few months [77] . Furthermore, the use of IGRAs during immunosuppressive treatment (including biologic therapy) is controversial, because the immunosuppression might decrease the production of IFN and interfere with the results [74] . Another inconvenience for both TST and
IGRAs is the lack of discrimination between latent and active TB [60] . Positive TST/IGRAs tests at baseline often remain positive despite a successful anti-TB treatment. In these cases careful monitoring for clinical signs and symptoms of active TB is recommended [78] .
According to the Tuberculosis Network European Trials Group (TBNET) consensus, the chemoprophylactic regimens recommended for LTBI include 6 or 9 months with isoniazid, 3 months of rifampicin plus isoniazid, or 4 months of rifampicin [79] . Another regimen used in the USA includes rifampicin and pyrazinamide for 2 months, although this regimen has been associated with a high number of side effects [80] .
The diagnostic tools for active TB infection include clinical assessment, cultures for M.
tuberculosis, staining for acid-fast bacilli, chest X-rays, and nucleic acid amplification assays [9] .
Although culture is considered the reference standard, in clinical practice the diagnosis and treatment of TB are usually based on the presence of abnormal radiologic findings or clinical suspicion [20] .
The recommendations for resuming biologic therapy in active TB patients are controversial.
According to the American College of Rheumatology (ACR), anti-TNF therapy can be initiated or resumed after 1 month of chemoprophylaxis for LTBI and after completion of therapy for active disease [78] .
The British Society for Rheumatology (BSR) accepts the continuation of biologic therapy during TB treatment if clinically indicated [81] .
Hernandez et al. [82] 
